Neuroptika today announced completion of enrollment in a Phase 2 clinical controlled, double-masked trial of NRO-1 for the treatment of patients with dry eye disease.

Neuroptika today announced positive data from the company's Phase 1 clinical trial to determine the safety, tolerability, and pharmacokinetics of topical NRO-1 in healthy subjects.

Neuroptika today announced that the first patient was enrolled in a Phase 2 clinical trial of NRO-1 for the treatment of dry eye disease.

Neuroptika today announced its initiation as a company to develop a novel therapeutic drug to protect and regenerate corneal nerves in ophthalmic diseases.